Clinical Trial

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-10; most recent amendment 2025-12-21.
Status change: Not Yet Recruiting → Recruiting 2024-07-03
Trial Details
NCT Number NCT06459973
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 252 participants
Start Date 2024-06-04
Primary Completion 2027-07-31 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-23